What Is Henoch-Schönlein Purpura?
Henoch-Schönlein purpura (HSP) is the most common vasculitic syndrome in children, typically presenting first with skin and joint findings, followed by gastrointestinal and kidney involvement. It is an IgA-mediated immune complex disease that causes inflammation of small blood vessels — capillaries, venules, and arterioles.
HSP typically affects the skin, intestines, kidneys, and joints, and is more common in winter and spring. It occurs most often around ages 4-5 and is slightly more common in boys. In our country, HSP is the most common childhood vasculitis. In about a third of cases, a link to group A streptococcal infection has been identified; other infections, certain vaccines, and medications have also been reported as possible triggers.
Diagnostic Criteria and Findings
According to international classification criteria, a diagnosis of HSP requires "palpable purpura" (a raised, touchable rash) plus at least one of the following:
Diffuse abdominal pain
Tissue biopsy (skin, kidney, etc.) showing IgA deposits
Acute arthritis or joint pain (arthralgia)
Evidence of kidney involvement (blood and/or protein in the urine)
Skin involvement is usually symmetric, often starting as a raised rash on the lower legs that quickly evolves into purpura; localized swelling of the hands, feet, and face can occur. Joint involvement is seen in about 70% of patients and does not leave lasting damage. Gastrointestinal symptoms (severe abdominal pain, vomiting, and rarely bowel telescoping/intussusception) occur in 50-70% of patients and typically follow the appearance of the rash.
Kidney Involvement
The main source of illness burden in HSP is kidney involvement, which typically appears within the first few weeks. About 30-70% of patients have mild blood and protein in the urine, while 1-5% go on to develop chronic kidney failure. Kidney involvement usually appears within the first 3 months. Persistent urine abnormalities, kidney dysfunction, or high blood pressure should prompt referral to a pediatric nephrologist.
Overall, the outcome in young children is generally good. Large cohort studies report kidney involvement in about 20% of cases, with long-term kidney survival close to 100%. In some children, symptoms that fully resolve can recur years later.
Treatment
Treatment mainly involves supportive care aimed at relieving symptoms such as joint pain and abdominal pain, typically with acetaminophen or nonsteroidal anti-inflammatory drugs. In patients with severe gastrointestinal symptoms, corticosteroids can rapidly improve symptoms; however, tapering the dose too quickly or stopping it early can trigger a flare. Selected patients with severe kidney involvement may need stronger immunosuppressive treatment. Any such treatment decision should be made in consultation with pediatric nephrology and rheumatology specialists.
Let's discuss your questions together.
Book appointment
